In this study, we showed that LXRβ and its target genes are overexpressed in pancreatic cancer and we applied an integrative -omics approach to characterize the mechanisms of action of a novel LXR modulator, 1E5, that we recently identified in a screen of putative LXR ligands for inhibitory activity in PDAC cells [8]. This evidence concerns the gene NR1H2 and pancreatic neoplasm.